Certain Systems, Devices, Software, Compositions, Chemicals, and Laboratory Supplies for Studying Proteins; Inv. No. 337-TA-3911 (Violation)

Seer, Inc. and The Brigham and Women’s Hospital, Inc. filed a Section 337 complaint against proposed respondent Nanomics Biotechnology Co., Ltd. alleging infringement of U.S. Patent Nos. 11,435,360; 11,630,112; 12,050,222; 12,228,566; and 12,590,948. The accused products are Nanomics’ Proteonano proteomics platform, including automated workstations, assay/enrichment kits, nanoparticles, reagents, software, and related laboratory consumables for protein/proteome analysis. The complaint targets competing nanoparticle-based proteomics technology used to enrich and analyze low-abundance proteins in biological samples, a commercially important area for mass-spectrometry-based biomarker discovery. Complainants allege Nanomics copied Seer’s Proteograph platform and seek a limited exclusion order, cease-and-desist order, and bond to block importation and U.S. commercialization of the accused products. Complainants assert direct, induced, and contributory infringement based on Nanomics’ importation, sale for importation, and post-importation sale/use of Proteonano workstations and enrichment kits. The complaint alleges a domestic industry through Seer’s U.S.-based development, manufacturing, research, engineering, support, and commercialization of Proteograph assay kits and automation instruments practicing the asserted patents. Requested relief includes institution of a Section 337 investigation, a limited exclusion order, cease-and-desist order, and bonding during the Presidential review period.